 |
 |

Olanzapine vs Haloperidol for Treatment of SchizophreniaReply
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In Reply: Drs Volavka and Citrome suggest that some patients in our study may have previously failed to improve with atypical antipsychotic drugs, thus biasing our results in favor of a negative effect of olanzapine. We think this conclusion is unlikely. We did not find that olanzapine was less effective in our study than in others, but rather that haloperidol was so much better, probably because we provided prophylactic benztropine. In fact, at entry into our study, 40% of patients were receiving an atypical antipsychotic, 37% were receiving haloperidol, and the rest were receiving other conventional agents. If anything, this would have biased the results against haloperidol, not olanzapine. Volavka et al1 have previously acknowledged that the findings of their study favoring olanzapine were invalid because " . . . we included patients who had failed to respond to haloperidol. However, those who showed a clear failure to respond to . . . [Full Text of this Article]
Robert Rosenheck, MD;
Deborah Perlick, PhD;
Stephen Bingham, PhD;
Joseph Collins, ScD
West Haven, Conn
RELATED ARTICLES
Olanzapine vs Haloperidol for Treatment of Schizophrenia
Jan Volavka and Leslie Citrome
JAMA. 2004;291(9):1064.
EXTRACT
| FULL TEXT
Olanzapine vs Haloperidol for Treatment of Schizophrenia
William M. Glazer
JAMA. 2004;291(9):1064-1065.
EXTRACT
| FULL TEXT
Olanzapine vs Haloperidol for Treatment of Schizophrenia
Mo Amin and Vijay S. Shukla
JAMA. 2004;291(9):1065.
EXTRACT
| FULL TEXT
Olanzapine vs Haloperidol for Treatment of Schizophrenia
Michal Kunz
JAMA. 2004;291(9):1065.
EXTRACT
| FULL TEXT
Olanzapine vs Haloperidol for Treatment of Schizophrenia
Lieuwe de Haan and Nico van Beveren
JAMA. 2004;291(9):1065.
EXTRACT
| FULL TEXT
Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial
Robert Rosenheck, Deborah Perlick, Stephen Bingham, Wen Liu-Mares, Joseph Collins, Stuart Warren, Douglas Leslie, Edward Allan, E. Cabrina Campbell, Stanley Caroff, June Corwin, Lori Davis, Richard Douyon, Lawrence Dunn, Denise Evans, Ede Frecska, John Grabowski, David Graeber, Lawrence Herz, Kong Kwon, William Lawson, Felicitas Mena, Javaid Sheikh, David Smelson, and Valerie Smith-Gamble
JAMA. 2003;290(20):2693-2702.
ABSTRACT
| FULL TEXT
|